# PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

> **NCT00589550** · PHASE1 · TERMINATED · sponsor: **Thomas Olencki** · enrollment: 1 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **BIOLOGICAL:** PEG-interferon alfa-2b
- **DRUG:** Sorafenib
- **GENETIC:** gene expression analysis
- **GENETIC:** polymerase chain reaction
- **GENETIC:** reverse transcriptase-polymerase chain reaction
- **OTHER:** flow cytometry
- **OTHER:** immunoenzyme technique
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00589550
- **Lead sponsor:** Thomas Olencki
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2015-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00589550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00589550, "PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00589550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*